About Us
Cyprotex is based in Macclesfield, nr. Manchester in the UK and is listed on the AIM market of the London Stock Exchange (CRX). Our company was established in 1999 and we work with in excess of 200 partners ranging from small Biotechs to large Pharma. We provide support for a wide range of experimental and computational ADME and PK services extending from early drug discovery through to IND submission.
Our core capabilities include:
- Our unique Cloe® Screen platform which is based on state of the art robotics and a highly sophisticated customised information management system. This dramatically reduces the cost and time in generating data whilst ensuring excellent reproducibility of data.
- Our Cloe® Select experimental service which provides support for later stage ADME and DMPK studies.
- A range of predictive technologies available under Cloe® Predict which take advantage of our extensive expertise in PBPK and QSAR modelling. Our proprietary Cloe® PK software product integrates core ADME and physicochemical properties to predict whole body pharmacokinetics.
|